Dear colleague,

We would like to invite you to participate in a new, global study on bronchiectasis.

In the past decade, randomised-controlled trials proved the efficacy of long-term macrolides in reducing exacerbations in adults with bronchiectasis. Global, real-life data to describe long-term macrolides use in bronchiectasis, along with their efficacy and safety, are needed. The GEMSTONE (Global Evaluation of Macrolides’ Safety and Treatment Outcomes in patieNts with bronchiEctasis) is an international, multicenter, observational, retrospective study aimed at evaluating long-term (at least three months) macrolide (either azithromycin, erythromycin, clarithromycin, or roxithromycin) treatment in adults with bronchiectasis.

At least 10 patients from each center are required to participate in the study.

The primary endpoint of the study is the change in the number of bronchiectasis exacerbations between the year prior and the year after the initiation of macrolide treatment. Only clinical data will be retrospectively collected through an online e-CRF. 

In case you are interested in participating in the study, we kindly ask you to fill a very short form at the following link:

Please submit you interest within 31 October 2023.

The full study protocol will be then sent to you along with the approval from the Ethical Committee (EC) of the coordinating center in Milan, Italy, in order for you to present the study at your local EC, if needed.

Best wishes,

The GEMSTONE Task Force

Doreen Addrizzo-Harris (New York, USA), Timothy Aksamit (Rochester, USA), Stefano Aliberti (Milan, Italy), James D. Chalmers (Dundee, United Kingdom), Hayoung Choi (Seoul, South Korea), Sanjay H. Chotirmall (Singapore), Raja Dhar (Kolkata, India), Lucy Morgan (Sydney, Australia), Mattia Nigro (Milan, Italy), Edoardo Simonetta (Milan, Italy), Jin-Fu Xu (Shangai, China).

This email has been sent to: «Email»
Click here to unsubscribe from this newsletter >